Asian Journal of Pharmacy and Technology

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Conceptual Aspects of Vesicular Drug Delivery System with Special Reference to Niosome


Affiliations
1 S.J. Thakkar Pharmacy College, Rajkot, India
     

   Subscribe/Renew Journal


Drug targeting is the ability of a therapeutic agent to act on the site of action which is prior to be desired having little or no interaction with non-target tissue. Niosomes are one of the best carriers for drug targeting. Niosomes are Microscopic lamellar structures and similar to liposomes which can be used as carrier of lipophilic and amphiphilic drugs. The size of niosome is very small (lies in Nano metric scale) than liposome, and have several advantage over liposomes. Niosomes are prepared by admixture of non-ionic surfactant of the alkyl or dialkyl polyglycerol ether class and cholesterol with subsequent hydration in aqueous media. Niosomes can be SUV (Small Unilamellar Vesicles), MLV (Multi lamellar Vesicles) or LUV (Large Unilamellar Vesicles). The method of preparation of niosome is based on liposome technology. The basic process of preparation is same like hydration by aqueous phase of the lipid phase which may be either a pure surfactant or mixture of surfactant or mixture of surfactant with cholesterol. Niosomes are important vehicle for drug delivery and being nonionic which is less toxic and improve the therapeutic index of drug by restricting action to target cells. Niosomes have shown good release profile and thus serve better option for drug delivery system.

Keywords

Niosome, Lamellar, Cholesterol, Surfactant, Vesicles
Subscription Login to verify subscription
User
Notifications
Font Size


  • Malhotra M, Jain NK. Niosome as drug carrier. Indian Drugs. 31; 1994:81-86.

  • Vyas SP, Khar RK . Targeted and Control Drug Delivery. CBS Publishers and Distributors,Chap.6, 2002, 1st ed: pp. 249-276.

  • Hunter C. Vesicular System (Niosomes and Liposomes) for Delivery of Sodium Stiboglucolate in Experimental Murine Visceral Leishmaniasis. Journal of Pharmacy and Pharmacology.40(3); 1988: 161.

  • Malhotra M, Jain NK. Niosome as Drug carrier. Indian Drugs. 31(3);1994: 81-86.

  • Buckton G., Harwood. Interfacialphenomena in Drug Delivery and Targeting Academic Publishers, Switzerland. 1995:154-155.

  • Hu C, Rhodes DG. Proniosomes: a novel Drug carrier preparation. International Journal of Pharmaceutics. 185; 1999: 23-25.

  • Kiwada H, et al. Application of synthetic Alkyl Glycoside vesicle as Drug carriers. I. Preparation and Physical Properties. Chemical and Pharmaceutical Bulletin. 33(2); 1985: 753-759.

  • Kiwada H, et al. Tissue Distribution and Pharmacokinetic Evaluation of the Targeting Efficiency of synthetic Alkyl Vesicles. Chemical and Pharmaceutical Bulletin. 33(6); 1985: 2475-2482.

  • Reddy DN, Udupa N. Formulation and Evaluation of Oral and Transdermal Preparation of Flubiprofen and piroxicam incorporated with Different carrier. Drug Development and Industrial Pharmacy. 1993:843-852.

  • Yoshioka T, et al. Preparation and Properties of vesicle (niosome) of sorbitan monoester (Span 20,40,60 and 80) and a Sorbitan trimester (Span 85). International Journal of Pharmaceutics.105; 1994: 1-6.

  • Carafa M, et al. Lidocaine-loaded non-ionic surfactant vesicle: Characterization and in vitro permeation studies. InternationalJournal of Pharmacetics.160; 1998: 51-59.

  • Niemiec SM, et al. Perifollicular Transgenic Expression of Human Interlukin-1 Receptor Antagonist Protein Following Topical Application of Novel Liposome-Plasmid DNA Formulation in vivo.STP Pharma science. 4; 1994: 145-149.

  • Guedj C, et al. Vesicle and other Supramolecular system from Biocompatible Synthetic Glycolipid with Hydrocarbon and/or Flurocarbon Chain. Chemistry and Physics of Lipids. 72; 1994: 153-173.

  • Gebicki JM, Hicks M. Preparation and Properties of vesicle enclosed by fatty acid membranes. Chemistry and Physics of Lipids. 16; 1976: 142-160.

  • Sahin NO. Nano materials and Nano system for Biomedical Application. Edited by Mozafari MR, Springer, The Netherlands. Chapter 4; 2007: pp.67-81.

  • Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicle (niosomes)in Drug delivery. International Journal of Pharmaceutics.185; 1999: 33-70.

  • Cosco D, et al. Novel PEG-coated niosomes based on bolasurfactant as drug carrier for 5-flurouracil. Biomedical Micro devices. 11; 2009: 1115-1125.

  • Baillie AJ. Non-ionic Surfactant Vesicles. Niosomes, as Delivery system for the Anti-Leishmanial Drug, Sodium Stribogluconate. Journal of Pharmacy and Pharmacology. 38; 1986: 502-505.

  • Rogerson A, et al. The distribution of doxorubicin in mice following administration in Niosomes. Journal of Pharmacy and Pharmacology. 40(5); 1998: 337-342.

  • Khandare JN, et al. Niosomes novel drug delivery system. The Eastern Pharmacist. 37; 1994: 61-64.

  • Patel RP. The ideal drug delivery system delivers drug at rate dictated by the need of the body over the period of treatment and it channels the active entity solely to the site of action. Available from: URL: http://www.pharmainfo.net/reviews/niosome-uniquedrug- delivery-system.

  • Naresh RA, et al. Anti-inflammatory activity of Niosome encapsulated diclofenac sodium with Tween-85 in Arthitic rats. International Journal of Pharmacology. 26; 1994: 46-48.

  • Udupa N. Niosome as drug carriers. In Jain NK’s controlled and Novel Drug Delivery. CBS Publishers and Distributors, New Delhi. pp. 292-303.

  • Chauhan S, Luorence MJ. The Preparation of Polyoxyethylene containing Non-ionic Surfactant Vesicle. Journal of Pharmacy and Pharmacology. 1989: 41-46.

  • Manconi M, et al. Niosomes as carrier for tretinoin II. Influence of vesicular incorporation on tretinoin photo stability. International Journal of Pharmaceutics. 260; 2003: 261-272.

  • Saha D, et al. Overview on Liposome as Drugs Carrier. Research Journal of Pharmaceutical Dosage Form and Technology. 2(6); 2010: 374-377.

  • Uchegbu IF, Florence AT. Distribution, Metabolism and Tumorocidal activity of Doxorubicin administered in sorbitan monostereate niosome in the mouse. Pharmaceutical Research. 12(7); 1995: 1019-1024.

  • Fang JY, et al. Effect of Liposome and Niosome on Skin permeation of enoxacin. International Journal of Pharmaceutics. 219; 2001:61-72.

  • Baidya S, Gupta BK. High Technology site-specific approach through Niosome Drug Delivery System. International Journal of Pharmaceutical Sciences. 32; 1998: 39-42.

  • .Carter KC, et al. The Therapeutic effect of Sodium Stibogluconate in BALB:C mice infected with Leishmania donorani is organ dependent. Journal of Pharmacy and Pharmacology. 40;1988: 370-373.

  • Yoshida H, et al. Niosome for oral delivery of peptide drugs. Journal Controlled Release. 21; 1992:145-153.

  • Bhaskaran S, Lakshmi PK. Niosomes- A Controlled and Novel Drug Delivery System. Acta Pharmaceutica Sciencia. 51; 2009: 27-32.

  • Yoshioka T, Florence AT. Vesicle (niosome)-in-water-in oil(v/w/o) emulsion in vitro study. International Journal of Pharmaceutics. 108; 1994: 117-123.

  • Hunter CA, et al. Vesicular system (niosome and liposome) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis. Journal of Pharmacy and Pharmacology. 40; 1988: 161-165.

  • Bhaskaran S, Panigrahi L. Formulation and Evaluation of Niosomes using Different Non-ionic Surfactant. Indian Journal of Pharmaceutical Sciences. 2002: 63.

  • Uchegbu IF, Florence AT. Nonionic Surfactant Vesicle (niosomes) Physical and Pharmaceutical Chemistry. Advances in Colloid and Interface Science. 1995:1.

  • Stafford S, et al. Drug effect on the size of chemically defined non-ionic surfactant vesicle. Journal of Pharmacy and Pharmacology. 40; 1988; 26.

  • Arunothayanun P. In vitro/ In vivo characterization of polyhedral niosomes. International Journal of Pharmaceutics. 183(1); 1999: 57-61.

  • Paolino D, et al. In vitro and In vivo evaluation of bola-surfactant containing niosomes for transdermal delivery. Biomedical Micro devices. 9; 2007: 421-433.

  • Ray A. Liposome in Drug delivery system. Asian Journal of Research and Pharmaceutical Science. 2(2); 2012: 41-44.

  • Dufes C, et al. Niosomes and Polymeric Chitosan based vesicles bearing Transferrin and glucose ligands for Drug Targeting. Pharmaceutical Research. 17; 2000: 1250-1258.

  • Ismail AA, et al. Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits. Pharmaceutical Science and Technology. 8; 2007: E1-E7.

  • Lala S, et al. Delivery in vivo of 14-deoxy-11- oxoandrographolide, an antileishmanial agent, by different drug carriers. Indian Journal of Biochemistry and Biophysics. 40; 2003: 169-174.

  • Jain CP, et al. Niosomal system for delivery of rifampicin to lymphatics.Indian Journal of Pharmaceutical Sciences. 68; 2006: 575-578.

  • Bayindir ZS, Yuksel N. Characterization of niosome prepared with various nonionic surfactant for paclitaxel oral delivery. Journal of Pharmaceutical Sciences. 99; 2010: 2049-2060.

  • Raja Naresh RA, et al. Kinetics and tissue Distribution of Niosomal Bleomycin in Tumor bearing Mice. Indian Journal of Pharmaceutical Sciences. 58; 1996: 230.

  • Oommen E, et al. Niosomes: A controlled and novel drug delivery system. Pharmacy and Pharmacology Communications. 5; 1998: 281-285.

  • Luciani A, et al. Nanoparticulate as Drug carrier. Radiology. 231; 2004: 135-142.

  • Pardakhty, et al. In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. International Journal of Pharmaceutics. 238; 2007: 130-141.

  • Lakshmi PK, et al. Niosomal methotrexate gel in the treatment of localized psoriasis: Phase I and Phase II studies. Indian Journal of Dermatology, Venereology, Leprology. 73; 2007:157-161.

  • Agarwal R, et al. Liposomal or Niosomal delivery system for ant psoriatic drug dithranol. International Journal of Pharmaceutics. 228; 2001: 43-52.

  • Sharma SK, Chauhan M. Niosomal oral suspension of fluconazole: formulation and in vitro evaluation. Journal of Pharmaceutical Research and Health Care. 11; 2009: 142-156.

  • Jain CP, Vyas SP. Preparation and characterization of niosomes containing Rifampicin for lung targeting.Journal of Microencapsulation. 12; 1995: 401-407.

  • Junyaprasert VB, et al. Effect of Charged and Non-ionic membrane additive on physicochemical properties and stability of niosome. AAPS Pharmaceutical Science and Technology. 9; 2008: 851-859.

  • Hofland, et al. Estradiol permeation from nonionic surfactant vesicle through Human Stratum Corneum in vitro.http://journals.ohiolink.edu/ejc/article.cgi?issn=07248741&i ssue=v11i0005&article=659_epfnsvthscivPharmaceutical Research. 11; 1995: 659-664.

  • Chandrakar S, Saraf S. Niosome - A Versatile Tool in Transdermal Drug Delivery. Research Journal of Pharmaceutical Dosage Forms and Technology. 1(1); 2009: 1- 4.

  • Abdelbary G, El-Gendy N. Niosome-encapsulated gentamycin for ophthalmic controlled delivery. AAPS Pharmaceutical Science and Technology. 9; 2008: 740-747.

  • Erdogan S, et al. In vivo behavior of vesicular urokinase. International Journal of Pharmaceutics. 295; 2005: 1-6.

  • Pillai GK, Salim ML. Enhancement inhibition of platelet aggregation in-vitro by niosome encapsulated indomethacin. International Journal of Pharmaceutics. 193; 1999: 123-127.

  • Shivanand P. Development and Characterization of Cefpoxime Proxetil Niosome. International Journal Pharma World Research. 1(3); 2010: 1-10.

  • Vangala A, et al. A Comparative study of cationic liposomes and niosome based adjuvant system for protein subunit vaccines: Characterization, Environmental Scanning Electron Microscopy analysis and immunization studies.Journal of Pharmacy and Pharmacology. 58; 2006: 787-799.

  • Hashim F, et al. Recent trends in Niosome as Vesicular Drug delivery system. Drug Delivery. 17; 2010: 282-287.

  • Desai AR, et al. Current Trends in Niosomes as a vesicular Drug delivery system. Drug Invention Today. 2; 2010: 325-327.

  • Arora R, Sharma A. Formulation and in vitro evaluation of Rifampicin-loaded Niosomes. Journal of Chemistry and Pharmaceutical Research. 2; 2010: 79-82.


Abstract Views: 487

PDF Views: 4




  • Conceptual Aspects of Vesicular Drug Delivery System with Special Reference to Niosome

Abstract Views: 487  |  PDF Views: 4

Authors

Rutvik P. Parmar
S.J. Thakkar Pharmacy College, Rajkot, India
Ramesh B. Parmar
S.J. Thakkar Pharmacy College, Rajkot, India

Abstract


Drug targeting is the ability of a therapeutic agent to act on the site of action which is prior to be desired having little or no interaction with non-target tissue. Niosomes are one of the best carriers for drug targeting. Niosomes are Microscopic lamellar structures and similar to liposomes which can be used as carrier of lipophilic and amphiphilic drugs. The size of niosome is very small (lies in Nano metric scale) than liposome, and have several advantage over liposomes. Niosomes are prepared by admixture of non-ionic surfactant of the alkyl or dialkyl polyglycerol ether class and cholesterol with subsequent hydration in aqueous media. Niosomes can be SUV (Small Unilamellar Vesicles), MLV (Multi lamellar Vesicles) or LUV (Large Unilamellar Vesicles). The method of preparation of niosome is based on liposome technology. The basic process of preparation is same like hydration by aqueous phase of the lipid phase which may be either a pure surfactant or mixture of surfactant or mixture of surfactant with cholesterol. Niosomes are important vehicle for drug delivery and being nonionic which is less toxic and improve the therapeutic index of drug by restricting action to target cells. Niosomes have shown good release profile and thus serve better option for drug delivery system.

Keywords


Niosome, Lamellar, Cholesterol, Surfactant, Vesicles

References